Market Cap (In USD)
26.58 Million
Revenue (In USD)
-
Net Income (In USD)
-52.55 Million
Avg. Volume
1.73 Million
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.521-17.17
- PE
- -
- EPS
- -
- Beta Value
- 0.397
- ISIN
- US00791X1000
- CUSIP
- 00775E102
- CIK
- 1622667
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Marc Forth
- Employee Count
- -
- Website
- http://www.aeonbiopharma.com
- Ipo Date
- 2023-07-24
- Details
- AEON Biopharma, Inc., a biopharmaceutical company, focuses on the development botulinum toxins for the treatment of debilitating medical conditions. It also develops 900 kDabotulinum toxin complex, ABP-450, for migraine, cervical dystonia, and gastroparesis. The company was formerly known as ALPHAEON Corporation and changed its name to AEON Biopharma, Inc. in December 2019. AEON Biopharma, Inc. was incorporated in 2012 and is headquartered in Newport Beach, California.
More Stocks
-
9898Weibo Corporation
9898
-
EMUEmu NL
EMU
-
CATCaterpillar Inc.
CAT
-
BWPT
-
TITMFTitomic Limited
TITMF
-
ACMAECOM
ACM
-
SHELTERSHELTER PHARMA LIMITED
SHELTER
-
6637